KR101311757B1 - 2-아미노-7,8-디히드로-6ｈ-피리도［4,3-ｄ］피리미딘-5-온 - Google Patents

2-아미노-7,8-디히드로-6ｈ-피리도［4,3-ｄ］피리미딘-5-온 Download PDF

Info

Publication number
KR101311757B1
KR101311757B1 KR1020087010134A KR20087010134A KR101311757B1 KR 101311757 B1 KR101311757 B1 KR 101311757B1 KR 1020087010134 A KR1020087010134 A KR 1020087010134A KR 20087010134 A KR20087010134 A KR 20087010134A KR 101311757 B1 KR101311757 B1 KR 101311757B1
Authority
KR
South Korea
Prior art keywords
amino
pyrimidin
phenyl
methyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087010134A
Other languages
English (en)
Korean (ko)
Other versions
KR20080057318A (ko
Inventor
티모시 디. 마챠쥬스키
신시아 엠. 샤퍼
크리스토퍼 맥브라이드
윌리엄 안토니오스-맥크레아
브랜든 엠. 더간
배리 에이치. 레빈
이 시아
마우린 맥켄나
엑스. 마이클 왕
크리스 멘덴홀
야신 주
바오칭 공
단 구
존 돌란
존 투린스키
크리스틴 브린너
젠하이 가오
다니엘 푼
폴 에이. 바르산티
샤오동 린
아브란 코스테일스
앨리스 리코
나탄 브래미어
테레사 픽
폴 에이. 렌호웨
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20080057318A publication Critical patent/KR20080057318A/ko
Application granted granted Critical
Publication of KR101311757B1 publication Critical patent/KR101311757B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020087010134A 2005-09-30 2006-09-28 2-아미노-7,8-디히드로-6ｈ-피리도［4,3-ｄ］피리미딘-5-온 Expired - Fee Related KR101311757B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72279605P 2005-09-30 2005-09-30
US60/722,796 2005-09-30
US83688606P 2006-08-09 2006-08-09
US60/836,886 2006-08-09
PCT/US2006/038181 WO2007041362A1 (en) 2005-09-30 2006-09-28 2-amino-7,8-dihydro-6h-pyrido[4,3-d] pyrimidin-5-ones

Publications (2)

Publication Number Publication Date
KR20080057318A KR20080057318A (ko) 2008-06-24
KR101311757B1 true KR101311757B1 (ko) 2013-09-26

Family

ID=37661234

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087010134A Expired - Fee Related KR101311757B1 (ko) 2005-09-30 2006-09-28 2-아미노-7,8-디히드로-6ｈ-피리도［4,3-ｄ］피리미딘-5-온

Country Status (31)

Country Link
US (2) US7671059B2 (enExample)
EP (1) EP1928875B1 (enExample)
JP (2) JP5036002B2 (enExample)
KR (1) KR101311757B1 (enExample)
AR (1) AR058072A1 (enExample)
AT (1) ATE514694T1 (enExample)
AU (1) AU2006297124B2 (enExample)
BR (1) BRPI0616701A2 (enExample)
CA (1) CA2624253C (enExample)
CR (1) CR9846A (enExample)
CY (1) CY1112028T1 (enExample)
DK (1) DK1928875T3 (enExample)
EA (1) EA016152B1 (enExample)
EC (1) ECSP088324A (enExample)
GE (1) GEP20115231B (enExample)
HR (1) HRP20110655T1 (enExample)
IL (1) IL190446A0 (enExample)
JO (1) JO2783B1 (enExample)
MA (1) MA29885B1 (enExample)
ME (1) ME01952B (enExample)
MY (1) MY143604A (enExample)
NO (1) NO342258B1 (enExample)
NZ (1) NZ566914A (enExample)
PE (1) PE20070621A1 (enExample)
PL (1) PL1928875T3 (enExample)
PT (1) PT1928875E (enExample)
RS (1) RS51795B (enExample)
SM (1) SMP200800029B (enExample)
TN (1) TNSN08143A1 (enExample)
TW (1) TWI373471B (enExample)
WO (1) WO2007041362A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CN101225083A (zh) * 2007-01-16 2008-07-23 北京摩力克科技有限公司 四氢喹唑啉酮类化合物及其用于制备治疗和预防病毒性疾病的药物的用途
GB2449293A (en) 2007-05-17 2008-11-19 Evotec Compounds having Hsp90 inhibitory activity
US8071766B2 (en) * 2008-02-01 2011-12-06 Takeda Pharmaceutical Company Limited HSP90 inhibitors
EP2334379A2 (en) 2008-09-26 2011-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Host cell kinases as targets for antiviral therapies against hcv infection
EP2370103B1 (en) * 2008-11-28 2016-03-23 Novartis AG Pharmaceutical combinations comprising an isoxazole derived hsp90-inhibitor and the her2 inhibitor trastuzumab
DK2370076T3 (en) * 2008-11-28 2017-04-03 Novartis Ag Pharmaceutical combination comprising an Hsp 90 inhibitor and an mTOR inhibitor
CN102227220A (zh) * 2008-11-28 2011-10-26 诺瓦提斯公司 用于治疗性治疗的Hsp90抑制剂
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
KR101690358B1 (ko) 2009-10-29 2017-01-09 제노스코 키나아제 억제제
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
EP2766015A1 (en) 2011-10-14 2014-08-20 Novartis AG 2-carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for the treatment of proliferative diseases
ITTO20111013A1 (it) 2011-11-03 2013-05-04 Dac Srl Composti farmaceutici
CN103664938A (zh) * 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 含有嘧啶并环的syk抑制剂
RU2015121424A (ru) 2012-11-07 2016-12-27 Новартис Аг Комбинированная терапия
US9677907B2 (en) * 2013-03-14 2017-06-13 Itron Inc Intelligent receptacle
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
KR101767859B1 (ko) * 2013-09-30 2017-08-11 다이호야쿠힌고교 가부시키가이샤 아자 2 고리형 화합물을 사용한 암 병용 요법
JP2017525734A (ja) * 2014-09-02 2017-09-07 ピエール、ファーブル、メディカマン 癌の治療において有用なイソキノリノン誘導体
KR20160035411A (ko) * 2014-09-23 2016-03-31 주식회사 오스코텍 LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
KR101653560B1 (ko) * 2016-02-02 2016-09-12 한국화학연구원 신규한 화합물 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 인플루엔자 바이러스 감염으로 인한 질환의 예방 또는 치료용 약학적 조성물
RU2629599C1 (ru) * 2016-09-28 2017-08-30 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ химиолучевого лечения опухолей прямой кишки и анального канала
JP7229158B2 (ja) 2017-06-09 2023-02-27 中外製薬株式会社 Ｎ－置換アミノ酸を含むペプチドの合成方法
US20230295108A1 (en) * 2020-06-26 2023-09-21 Nihon Nohyaku Co., Ltd. Aryltetrahydropyridine derivative or salt thereof, insecticidal agent containing the compound, and method of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192783A1 (en) 1984-09-07 1986-09-03 Mitsui Petrochemical Industries, Ltd. 2-piperazinopyrimidine derivatives and process for their preparation
EP0278742A2 (en) 1987-02-11 1988-08-17 May & Baker Limited Cyclic diones

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1307786C (en) 1984-12-14 1992-09-22 Keiichi Yokoyama Quinazoline derivatives and antihypertensive preparations containing same as effective components
KR100639772B1 (ko) * 2001-02-12 2006-10-30 에프. 호프만-라 로슈 아게 6-치환된 피리도-피리미딘
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
EP2332527A3 (en) 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2006074293A2 (en) 2005-01-07 2006-07-13 President And Fellows Of Harvard College Bicyclic dihydropyrimidines as eg5 inhibitors
US20070027150A1 (en) 2005-04-14 2007-02-01 Bellamacina Cornelia R 2-Amino-quinazolin-5-ones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0192783A1 (en) 1984-09-07 1986-09-03 Mitsui Petrochemical Industries, Ltd. 2-piperazinopyrimidine derivatives and process for their preparation
EP0278742A2 (en) 1987-02-11 1988-08-17 May & Baker Limited Cyclic diones

Also Published As

Publication number Publication date
GEP20115231B (en) 2011-06-10
AU2006297124A1 (en) 2007-04-12
AR058072A1 (es) 2008-01-23
MA29885B1 (fr) 2008-10-03
EA016152B1 (ru) 2012-02-28
DK1928875T3 (da) 2011-10-03
CY1112028T1 (el) 2015-11-04
SMAP200800029A (it) 2008-05-07
ECSP088324A (es) 2008-04-28
US20070123546A1 (en) 2007-05-31
ATE514694T1 (de) 2011-07-15
CR9846A (es) 2008-08-01
MY143604A (en) 2011-06-15
CA2624253A1 (en) 2007-04-12
HRP20110655T1 (hr) 2011-10-31
BRPI0616701A2 (pt) 2011-06-28
JP2009510108A (ja) 2009-03-12
ME01952B (en) 2011-12-31
EP1928875A1 (en) 2008-06-11
JP5036002B2 (ja) 2012-09-26
PT1928875E (pt) 2011-09-06
RS51795B (sr) 2011-12-31
JP2012158611A (ja) 2012-08-23
EA200800992A1 (ru) 2008-10-30
JO2783B1 (en) 2014-03-15
EP1928875B1 (en) 2011-06-29
WO2007041362A1 (en) 2007-04-12
TWI373471B (en) 2012-10-01
NO20082069L (no) 2008-06-09
NO342258B1 (no) 2018-04-30
PE20070621A1 (es) 2007-09-06
IL190446A0 (en) 2008-11-03
NZ566914A (en) 2011-09-30
KR20080057318A (ko) 2008-06-24
CA2624253C (en) 2015-06-16
PL1928875T3 (pl) 2011-11-30
AU2006297124B2 (en) 2011-12-08
TW200728304A (en) 2007-08-01
US20100004237A1 (en) 2010-01-07
TNSN08143A1 (en) 2009-07-14
SMP200800029B (it) 2008-05-07
HK1118823A1 (en) 2009-02-20
US7671059B2 (en) 2010-03-02

Similar Documents

Publication Publication Date Title
KR101311757B1 (ko) 2-아미노-7,8-디히드로-6ｈ-피리도［4,3-ｄ］피리미딘-5-온
TWI527800B (zh) 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
US20040132730A1 (en) Inhibitors of TGFbeta
US7232824B2 (en) Quinazoline derivatives as medicaments
KR20080006614A (ko) 증식 질환의 치료에 유용한 ｈｓｐ90 억제제인2-아미노-퀴나졸린-5-온
CN101616667A (zh) 可用作激酶抑制剂的杂环酰胺化合物
CN101805309A (zh) 用作组蛋白脱乙酰基酶抑制剂的苯甲酰胺衍生物
HU230787B1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
PL209412B1 (pl) Środek leczniczy obejmujący pochodne chinolinonu w połączeniu z lekiem przeciwnowotworowym, oraz zastosowanie pochodnych chinolinonu do wytwarzania środka leczniczego w połączeniu z lekiem przeciwnowotworowym
KR102374033B1 (ko) 특정 단백질 키나제 억제제
CN101287734B (zh) 2-氨基-7,8-二氢-6H-吡啶并[4,3-d]嘧啶-5-酮
EP1655297A1 (en) Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
ES2369707T3 (es) 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidin-5-onas, procedimiento para su preparación y composiciones farmacéuticas que contienen las mismas.
HK1118823B (en) 2-amino-7,8-dihydro-6h-pyrido(4,3-d)pyrimidin-5-ones, process for their preparation and pharmaceutical compositions containing the same
HK1123801A (zh) 2-氨基-7，8-二氢-6h-吡啶并[4，3-d]嘧啶-5-酮
HK1122275A (en) 2-amino-quinazolin-5-ones as hsp90 inhibitors useful in treating proliferation diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20180816

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20190918

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20190918

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000